<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ibogaine - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/psychedelics/">Psychedelics</a> ‚Üí <span>Ibogaine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üåø Ibogaine</h1>
        <h2 class="chemical-name">12-Methoxyibogamine</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Ibogaine" 
                data-category="Psychedelics" 
                data-chemical="12-Methoxyibogamine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Traditional Names</h4>
              <span>Iboga</span> ‚Ä¢ <span>Eboka</span> ‚Ä¢ <span>Sacred Wood</span> ‚Ä¢ <span>Ghost Medicine</span>
            </div>
            <div class="name-category">
              <h4>Clinical Names</h4>
              <span>Ibogaine HCl</span> ‚Ä¢ <span>Addiction Interrupter</span> ‚Ä¢ <span>Reset Medicine</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Ibo</span> ‚Ä¢ <span>Tree of Life</span> ‚Ä¢ <span>Vision Root</span> ‚Ä¢ <span>Cure</span>
            </div>
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>12-Methoxyibogamine</span> ‚Ä¢ <span>Ibogaine Hydrochloride</span> ‚Ä¢ <span>Tabernanthe Extract</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category psychedelic">Psychedelic</span>
          <span class="legal-status schedule-1">Schedule I (US)</span>
          <span class="duration extreme">12-36 hours</span>
          <span class="medical">Medical Use</span>
          <span class="natural">Natural Origin</span>
          <span class="extreme">Extreme Duration</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/ibogaine.jpg" alt="Iboga root bark and ibogaine crystals" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÇ‚ÇÄH‚ÇÇ‚ÇÜN‚ÇÇO</p>
            <p>MW: 310.44 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Ibogaine (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to cream-colored crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline powder, sometimes slightly sticky</li>
            <li><strong>Odor:</strong> Faint, slightly bitter medicinal smell</li>
            <li><strong>Taste:</strong> Intensely bitter, numbing to tongue</li>
            <li><strong>Solubility:</strong> Soluble in water and alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Natural & Processed Forms</h4>
          <ul>
            <li><strong>Root Bark:</strong> Brown fibrous bark from Tabernanthe iboga tree</li>
            <li><strong>Total Alkaloid (TA):</strong> Brown extract containing ~60% ibogaine + other alkaloids</li>
            <li><strong>Ibogaine HCl:</strong> Purified white crystalline powder (pharmaceutical grade)</li>
            <li><strong>Capsules:</strong> Measured doses in gelatin capsules for clinical use</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Purity Concerns</h4>
          <p><strong>Root Bark:</strong> Variable alkaloid content (1-10%), may contain other cardiotoxic compounds</p>
          <p><strong>Extracts:</strong> Quality varies dramatically - some contain dangerous impurities</p>
          <p><strong>Synthetic:</strong> Underground synthesis may produce toxic byproducts</p>
          <p><strong>Critical:</strong> Only pharmaceutical-grade ibogaine should be used for addiction treatment</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Microdose</span>
          <span class="dose-amount">25-100mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Psychoactive</span>
          <span class="dose-amount">100-300mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Therapeutic</span>
          <span class="dose-amount">300-800mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Flood Dose</span>
          <span class="dose-amount">800-1200mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">High Flood</span>
          <span class="dose-amount">1200mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>‚ö†Ô∏è Critical Dosage Information</h4>
        <ul>
          <li><strong>Weight-based:</strong> Flood doses typically 15-25mg/kg bodyweight</li>
          <li><strong>Medical supervision:</strong> Required for all therapeutic doses due to cardiac risks</li>
          <li><strong>Pre-screening:</strong> ECG, liver function, kidney function mandatory</li>
          <li><strong>Single use:</strong> Most people only need one flood dose in lifetime</li>
          <li><strong>No redosing:</strong> Never redose - effects last 12-36 hours</li>
          <li><strong>Metabolism:</strong> Slow metabolizers at higher risk of cardiac complications</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>EXTREME WARNING:</strong> Ibogaine can cause fatal cardiac arrhythmias. Deaths have occurred at therapeutic doses. Only use under qualified medical supervision with cardiac monitoring.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Extended Timeline (Flood Dose)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-2:00</span>
          <span class="effect">Onset - nausea, ataxia, initial visionary state</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-8:00</span>
          <span class="effect">Visionary phase - intense closed-eye visions, life review</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-20:00</span>
          <span class="effect">Introspective phase - deep psychological processing</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+20:00-36:00</span>
          <span class="effect">Integration phase - gradual return with insights</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+36:00+</span>
          <span class="effect">Post-experience - weeks/months of neurological reset</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Therapeutic Effects</h4>
          <ul>
            <li>Dramatic reduction in addiction cravings</li>
            <li>Profound psychological insights</li>
            <li>Reset of neurological reward pathways</li>
            <li>Life review and trauma processing</li>
            <li>Spiritual/mystical experiences</li>
            <li>Enhanced neuroplasticity</li>
            <li>Months of reduced depression/anxiety</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Challenging Effects</h4>
          <ul>
            <li>Severe nausea and vomiting (universal)</li>
            <li>Loss of motor coordination (ataxia)</li>
            <li>Intense psychological confrontation</li>
            <li>Sleep disruption for weeks</li>
            <li>Extreme fatigue during recovery</li>
            <li>Temporary cognitive impairment</li>
            <li>Potential cardiac arrhythmias</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Ibogaine is a complex multi-target alkaloid that acts primarily as an NMDA receptor antagonist (similar to ketamine) while also affecting multiple neurotransmitter systems. Its unique addiction-interrupting properties stem from its ability to "reset" neuroadaptations caused by chronic drug use, particularly in dopaminergic reward circuits.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptors</strong></span>
            <span class="affinity">Non-competitive antagonist</span>
            <span class="function">Primary dissociative effects, neuroplasticity</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ∫-Opioid receptors</strong></span>
            <span class="affinity">Moderate agonist activity</span>
            <span class="function">Anti-addictive effects, dysphoria reduction</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œº-Opioid receptors</strong></span>
            <span class="affinity">Weak agonist (noribogaine)</span>
            <span class="function">Prevents withdrawal symptoms</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ¥-Opioid receptors</strong></span>
            <span class="affinity">Weak agonist activity</span>
            <span class="function">Mood stabilization</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Serotonin transporter</strong></span>
            <span class="affinity">Moderate inhibition</span>
            <span class="function">Antidepressant-like effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Nicotinic Œ±3Œ≤4</strong></span>
            <span class="affinity">Competitive antagonist</span>
            <span class="function">Reduces nicotine craving</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> O-demethylation by CYP2D6 ‚Üí Noribogaine (active metabolite)</p>
          <p><strong>Noribogaine:</strong> 10x longer half-life, responsible for long-term anti-craving effects</p>
          <p><strong>Ibogaine half-life:</strong> 7-11 hours (highly variable)</p>
          <p><strong>Noribogaine half-life:</strong> 28-149 hours (extremely variable)</p>
          <p><strong>Bioavailability:</strong> ~100% oral administration</p>
          <p><strong>Peak plasma:</strong> 2-4 hours after oral dose</p>
          <p><strong>CYP2D6 polymorphism:</strong> Poor metabolizers at extreme risk of cardiac toxicity</p>
        </div>

        <h4>Cardiac Toxicity Mechanisms</h4>
        <div class="neurotoxicity-info">
          <p><strong>hERG channel block:</strong> Delays cardiac repolarization, causes QT prolongation</p>
          <p><strong>Torsades de pointes:</strong> Life-threatening arrhythmia can occur hours post-dose</p>
          <p><strong>Noribogaine accumulation:</strong> Active metabolite also cardiotoxic with very long half-life</p>
          <p><strong>Individual variation:</strong> Genetic polymorphisms create 10-fold variation in sensitivity</p>
          <p><strong>Conduction delays:</strong> Can affect all aspects of cardiac electrical system</p>
        </div>

        <h4>Neuroplasticity & Addiction Interruption</h4>
        <ul>
          <li><strong>GDNF upregulation:</strong> Increases growth factors that repair dopamine neurons</li>
          <li><strong>Synaptic plasticity:</strong> Resets maladaptive neural pathways</li>
          <li><strong>Gene expression:</strong> Long-term changes in addiction-related gene expression</li>
          <li><strong>Dendritic sprouting:</strong> Promotes new neural connections</li>
          <li><strong>Default mode network:</strong> Reorganizes brain's introspective networks</li>
          <li><strong>Memory reconsolidation:</strong> Allows reprocessing of traumatic memories</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® LIFE-THREATENING RISKS</h4>
          <ul>
            <li><strong>Cardiac arrest:</strong> Can occur up to 48 hours post-dose</li>
            <li><strong>QT prolongation:</strong> Fatal arrhythmias even at therapeutic doses</li>
            <li><strong>Respiratory depression:</strong> Risk increases with other depressants</li>
            <li><strong>Seizures:</strong> Rare but documented, especially with impure extracts</li>
            <li><strong>Liver toxicity:</strong> Severe hepatotoxicity reported</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Mandatory Precautions</h4>
          <ul>
            <li>Medical supervision with cardiac monitoring required</li>
            <li>Pre-screening: ECG, liver function, electrolytes, CYP2D6 testing</li>
            <li>24-48 hour cardiac monitoring post-dose</li>
            <li>Emergency resuscitation equipment on-site</li>
            <li>Experienced medical team familiar with ibogaine</li>
            <li>No other medications for 2+ weeks before/after</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Absolute Contraindications</h4>
        <p><strong>NEVER use if you have:</strong> Any heart condition, QT prolongation, liver disease, kidney disease, seizure history, eating disorders, pregnancy, psychiatric instability, or if taking ANY medications (especially antidepressants, antipsychotics, or other cardioactive drugs).</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ FATAL COMBINATIONS</h4>
          <ul>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome + increased cardiac risk</li>
            <li><strong>MAOIs:</strong> Hypertensive crisis + serotonin syndrome</li>
            <li><strong>Antipsychotics:</strong> Additive QT prolongation - potentially fatal</li>
            <li><strong>Class IA/III antiarrhythmics:</strong> Extreme QT prolongation</li>
            <li><strong>Tramadol:</strong> Seizures + serotonin syndrome</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Benzodiazepines:</strong> Respiratory depression</li>
            <li><strong>Opioids:</strong> Respiratory depression (even at low doses)</li>
            <li><strong>Alcohol:</strong> Increased cardiac toxicity</li>
            <li><strong>Stimulants:</strong> Increased cardiac stress</li>
            <li><strong>Other psychedelics:</strong> Unpredictable interactions</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Avoid Completely</h4>
          <ul>
            <li><strong>ALL psychiatric medications</strong> - 2+ week washout required</li>
            <li><strong>Supplements:</strong> St. John's Wort, 5-HTP, SAM-e</li>
            <li><strong>Recreational drugs:</strong> All substances for 1+ week before</li>
            <li><strong>Prescription drugs:</strong> Virtually all require medical clearance</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule I</strong> - Illegal for all uses except FDA-approved research. No legal treatment centers.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá≤üáΩ Mexico</h4>
            <p><strong>Unscheduled</strong> - Legal treatment centers operate in gray area. Quality varies dramatically.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá¶ Canada</h4>
            <p><strong>Controlled</strong> - Special Access Program allows supervised medical use for addiction.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá≥üáø New Zealand</h4>
            <p><strong>Class A</strong> - Illegal but government funding clinical trials for addiction treatment.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Therapeutic Development</h4>
          <p>FDA granted "Breakthrough Therapy" designation for ibogaine addiction treatment in 2023. Multiple companies developing safer ibogaine derivatives. Legal treatment likely within 5-10 years in select jurisdictions.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">Ancient</span>
          <p>Used for millennia by Bwiti people of Gabon for spiritual initiation</p>
        </div>
        <div class="history-event">
          <span class="year">1901</span>
          <p>Ibogaine first isolated from Tabernanthe iboga by French researchers</p>
        </div>
        <div class="history-event">
          <span class="year">1960s</span>
          <p>Chilean psychiatrist Claudio Naranjo explores therapeutic potential</p>
        </div>
        <div class="history-event">
          <span class="year">1962</span>
          <p>Howard Lotsof accidentally discovers anti-addictive properties</p>
        </div>
        <div class="history-event">
          <span class="year">1970</span>
          <p>US scheduling as Schedule I ends most research</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Underground treatment centers emerge in developing countries</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Rising deaths lead to calls for medical protocols</p>
        </div>
        <div class="history-event">
          <span class="year">2020s</span>
          <p>FDA breakthrough designation revives legitimate research</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Traditional & Modern Context</h4>
        <p>In Bwiti tradition, iboga is consumed during multi-day initiation ceremonies involving the entire community. The Western medical approach of isolated flood doses represents a dramatic departure from indigenous practices, which may explain both the therapeutic potential and the safety risks of modern ibogaine treatment.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Opioid Addiction Treatment</h4>
          <p>Multiple Phase II trials showing 50-80% abstinence rates at 12 months post-treatment. Mindmed's 18-MC (ibogaine derivative) in Phase II trials with reduced cardiac risk profile.</p>
        </div>
        
        <div class="research-item">
          <h4>Alcohol Use Disorder</h4>
          <p>Brazilian and Mexican clinics report high success rates for alcohol addiction, though controlled trials are limited.</p>
        </div>
        
        <div class="research-item">
          <h4>Cocaine/Stimulant Addiction</h4>
          <p>Promising early results for cocaine addiction treatment, with some studies showing sustained abstinence.</p>
        </div>
        
        <div class="research-item">
          <h4>PTSD & Depression</h4>
          <p>Secondary benefits observed in addiction patients include dramatic improvements in co-occurring PTSD and depression.</p>
        </div>
        
        <div class="research-item">
          <h4>Safer Analogues</h4>
          <p>Multiple pharmaceutical companies developing ibogaine derivatives (18-MC, tabernanthalog) with reduced cardiac toxicity while maintaining anti-addictive properties.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://maps.org/research/ibogaine">MAPS Ibogaine Research</a> - Scientific studies</li>
          <li><a href="https://ibogaine.org/">ICEERS</a> - Harm reduction protocols</li>
          <li><a href="https://www.globalibogainealliance.org/">Global Ibogaine Alliance</a> - Safety guidelines</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Treatment Centers</h4>
        <ul>
          <li><a href="https://ibogainealliance.org/providers/">Verified Providers</a> - Screened treatment centers</li>
          <li><strong>Warning:</strong> Many centers lack proper medical oversight</li>
          <li><strong>Research thoroughly:</strong> Deaths occur at unqualified facilities</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Education</h4>
        <ul>
          <li><a href="https://ibogaine.org/harm-reduction/">ICEERS Harm Reduction</a> - Safety protocols</li>
          <li><a href="https://www.reddit.com/r/Ibogaine/">/r/Ibogaine</a> - Community experiences</li>
          <li><a href="https://sapiensoup.com/ibogaine">Sapien Soup Guide</a> - Comprehensive information</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/profile.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/friends.js"></script>
</body>
</html>